Delta-Fly Pharma surges on data suggesting DFP-17729 may extend OS in phase 2/3 trial
Shares of Delta-Fly Pharma, Inc. <4598> surged after releasing an interim data update after the market close on Aug. 31 for its ongoing Phase 2/3 trial of DFP-17729 (a tumor microenvironment modulator) in Japan, targeting patients with unresectable, recurrent, or advanced pancreatic cancer receiving third-line or later treatment.
Delta-Fly Pharma said no adverse effects impacting trial continuation have been observed to date. Under double-blind conditions, the overall survival rate across all subjects stands at 71.8%, with a median overall survival (OS) of about 7.2 months.
Given that advanced pancreatic cancer patients receiving third-line or later treatment face a poor prognosis - with a reported median OS of roughly 3 to 4 months - Delta-Fly Pharma noted that while the trial is ongoing and final efficacy assessments are pending, the results suggest potential to extend OS.
Source: MINKABU PRESS
*Translated by generative AI. Click here for the original article.
Related Articles
-
TETSUJIN Holdings falls for fourth consecutive session after TSE designates stock as supervision issue effective Sept. 1
Tue Sep 1, 2026 10:29 am JST Catalyst -
MEIDENSHA reverses lower as interim dividend forecast of 83 yen draws limited market reaction
Tue Sep 1, 2026 10:21 am JST Catalyst -
SWCC falls as profit-taking dominates despite 1-for-5 stock split announcement with Sept. 30 record date
Tue Sep 1, 2026 10:10 am JST Catalyst -
Tokyo Prime market breadth at 10 a.m.: 778 gainers, 729 decliners
Tue Sep 1, 2026 10:04 am JST Market -
TOKYO ENERGY & SYSTEMS seen as laggard play on power infrastructure theme as earnings growth accelerates
Tue Sep 1, 2026 10:00 am JST Catalyst -
Terra Drone reverses early losses to post sharp gains after announcing strategic partnership with Malaysian defense firm
Tue Sep 1, 2026 9:53 am JST Catalyst -
Ishii Food rebounds for first time in four sessions on baby food market entry plan
Tue Sep 1, 2026 9:46 am JST Catalyst -
KOSAIDO Holdings rebounds as treasury share cancellation expected to bring float ratio into compliance
Tue Sep 1, 2026 10:05 am JST Catalyst -
RACCOON HOLDINGS rises after reporting double-digit revenue and profit growth in May-July quarter
Tue Sep 1, 2026 9:49 am JST Catalyst -
TWINBIRD hits limit-down as it opposes Japanet's TOB offer
Tue Sep 1, 2026 10:02 am JST Catalyst